MedTrace Logo

Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets

NCT01208155 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-12-08

No results posted yet for this study

Summary

Study in healthy males to assess bioavailability of 4 different fostamatinib tablets

Conditions

  • Bioavailability
  • Pharmacokinetics

Interventions

DRUG

Fostamatinib

Oral tablets, 50 mg x 2, single dose

DRUG

Fostamatinib

Oral tablets, 100 mg Batch 1, single dose

DRUG

Fostamatinib

Oral tablets, 100 mg Batch 2, single dose

DRUG

Fostamatinib

Oral tablets, 100 mg Batch 3, single dose

Sponsors & Collaborators

Principal Investigators

  • Mark Layton, MD · AstraZeneca

  • Carlos Prendes, MD · Quintiles, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01208155 on ClinicalTrials.gov